FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
about
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemiaPrognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyAllogeneic stem cell transplantation in first complete remissionMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaProgress in acute myeloid leukemiaCIViC databaseMutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.Significance of oncogenes and tumor suppressor genes in AML prognosis.Integrative meta-analysis of differential gene expression in acute myeloid leukemiaGAS6 expression identifies high-risk adult AML patients: potential implications for therapyOutcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaPhase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.The Biology and Targeting of FLT3 in Pediatric Leukemia.Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasPrognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.Molecular diagnostics in acute leukemias.FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia.Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology GroupClinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
P2860
Q24612217-689CC1FC-46F5-453D-946B-F0F9BAAF74D9Q24643738-24F836D1-89EA-4C6A-A5CA-AF07F8D5C51BQ26996818-9773D66B-22C1-4B8F-AA39-3A87BE5F343BQ26998811-8C3D79A1-F865-4E10-877B-2FD237762B60Q27024006-8975A392-5E3A-4274-9B25-27B61D05F07FQ27612411-BABDA929-0DFE-498C-A66C-E589D9A81F5DQ27851423-43090416-96F9-4182-909C-D9F37D974335Q27851436-1B5D4217-9459-49F3-8D00-98C62F980F1CQ27851545-8E8ABBD1-2441-4CFF-93F3-2431433BFD7BQ27851621-317A90F7-1D55-49B8-8EDE-C9597937359CQ27851679-C505AB0C-00DD-45A9-B575-5BC3235C1B84Q27851713-A1E93D2F-3E80-4B49-B8C8-A84876F25DA8Q27851839-8A19CCAD-CF39-4786-A900-2F40BF057CDEQ27852520-5AD8E1C0-8D2D-4AD5-9ABD-C02BCFE56ADBQ27853004-7C83456F-5A8B-4ECA-96BF-3967798C2EBAQ30250315-5897E181-EB87-4CA4-ACB0-9557BA43FC39Q33538043-CC362A10-8108-4352-A2AA-85CA030D7FB7Q33717707-90412807-3CFB-4DE0-8772-8B2D7BD5D361Q33774504-D75F454F-0DB9-49FB-98A8-69FD244129F7Q33897586-7251EE8E-EA0C-472C-86E8-85ED082995F4Q33913329-644A0177-08ED-4A38-A7DE-368B75D36E72Q33986236-5094493E-4BAB-488F-A451-61F720AC47B5Q34011740-68237ECB-BA82-4158-9A70-A2DEB0D026E0Q34095013-C0F52BE0-8ABD-4392-947B-B8281675FDB4Q34229555-46D01D3F-4D38-420C-923E-1DF611B1091AQ34285937-A8FCE5E9-E9F7-454B-B3D3-7A6965D2E8E8Q34340438-A43F7CC1-A9CB-4A81-8510-0E9BB6E5CEC0Q34451540-3002289C-12BA-4DED-9FC1-E46507649F70Q34477821-AF9A29CA-2DB9-4CC3-B40A-CBA912E8E8C4Q34667807-44CC91F1-3794-49D8-92D6-0CCF7FFA2785Q35007333-FA68FF2F-64A1-474E-A1C0-67308F2979F9Q35048217-DEB74805-FDF8-41BF-8171-D0A532F2B483Q35265946-6E4F75F2-F841-4B6B-A038-7DABA160832EQ35485832-09F96EA6-3F74-46CD-ACFD-808159BE4A32Q35525433-9D53DCB2-D3CD-47B2-92F0-074C65285393Q35794120-3C1B4E4F-D118-46BC-9C5D-A1CF2A2DBC2CQ35836868-36342B6D-A9E4-44E0-8D71-BB9582D3D60CQ35920569-A8BEB505-6B6A-4453-97EF-8685CFCB4909Q36012998-779C2389-54F4-4466-872C-0DD88F6762B6Q36057877-AA2613DE-992D-4FC3-8B00-2B9606B766CC
P2860
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@ast
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@en
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@nl
type
label
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@ast
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@en
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@nl
altLabel
FLT3 D835/I836 mutations are a ...... 3 internal tandem duplications
@en
prefLabel
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@ast
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@en
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@nl
P2093
P2860
P50
P1433
P1476
FLT3 D835/I836 mutations are a ...... internal tandem duplications.
@en
P2093
Amy S Ruppert
Bayard L Powell
Christian Langer
Claudia D Baldus
Frederick Racke
Jonathan E Kolitz
Michael A Caligiuri
Michael D Radmacher
Peter Paschka
P2860
P304
P356
10.1182/BLOOD-2007-08-107946
P407
P577
2008-02-01T00:00:00Z